Among all diagnosed cases of invasive breast cancer, approximately 15–20% are triple-negative breast cancer (TNBC) [1], a cancer type without estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). This evidence concerns the gene ERBB2 and invasive breast carcinoma.